

Alessia Mennitto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4150824/publications.pdf>

Version: 2024-02-01

38
papers

1,193
citations

393982

19
h-index

395343

33
g-index

38
all docs

38
docs citations

38
times ranked

2649
citing authors

#	ARTICLE	IF	CITATIONS
1	Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21). <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 115-121.	1.1	5
2	Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review. <i>Cancers</i> , 2022, 14, 1792.	1.7	15
3	Effects of cabozantinib on bone turnover markers in real-world metastatic renal cell carcinoma. <i>Tumori</i> , 2021, 107, 542-549.	0.6	4
4	Radical metastasectomy followed by sorafenib versus observation in patients with clear cell renal cell carcinoma: extended follow-up of efficacy results from the randomized phase II RESORT trial. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 261-268.	1.3	8
5	Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer. <i>Cancers</i> , 2021, 13, 4522.	1.7	22
6	Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1644.	1.3	48
7	Current Understanding of Urachal Adenocarcinoma and Management Strategy. <i>Current Oncology Reports</i> , 2020, 22, 9.	1.8	23
8	Angiogenesis and Immunity in Renal Carcinoma: Can We Turn an Unhappy Relationship into a Happy Marriage?. <i>Journal of Clinical Medicine</i> , 2020, 9, 930.	1.0	25
9	Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 139, 53-66.	2.0	137
10	Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 42-45.	0.6	20
11	Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases. <i>Clinical Colorectal Cancer</i> , 2019, 18, 34-43.e6.	1.0	7
12	Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles. <i>Clinical Breast Cancer</i> , 2019, 19, e306-e318.	1.1	16
13	Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials. <i>British Journal of Cancer</i> , 2018, 118, 955-965.	2.9	17
14	Management of Metastatic Collecting Duct Carcinoma: An Encouraging Result in a Patient Treated With Cabozantinib. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e521-e523.	0.9	17
15	The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer. <i>Scientific Reports</i> , 2018, 8, 8703.	1.6	43
16	Does ^{18}F -FDG-PET still play a role in metastatic renal cell carcinoma?. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2017, 61, 250-251.	0.9	0
17	Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer. <i>Annals of Oncology</i> , 2017, 28, 1015-1022.	0.6	24
18	Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 365-373.	1.1	12

#	ARTICLE	IF	CITATIONS
19	Everolimus treatment for neuroendocrine tumors: latest results and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 183-188.	1.4	20
20	Multimodal treatment of advanced renal cancer in 2017. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 1395-1402.	1.3	23
21	Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions. <i>Oncology</i> , 2017, 93, 279-286.	0.9	9
22	Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?. <i>Drugs in R and D</i> , 2017, 17, 461-467.	1.1	5
23	Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2414-2422.	3.2	148
24	Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. <i>Annals of Oncology</i> , 2017, 28, 555-561.	0.6	43
25	Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases. <i>Clinical Colorectal Cancer</i> , 2017, 16, e191-e198.	1.0	12
26	Treatment of Advanced Renal Cell Carcinoma: Recent Advances and Current Role of Immunotherapy, Surgery, and Cryotherapy. <i>Tumori</i> , 2017, 103, 15-21.	0.6	8
27	Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 148-163.	0.6	81
28	IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in <i>RAS</i> mutant metastatic colorectal cancer patients. <i>Oncotarget</i> , 2017, 8, 16887-16898.	0.8	28
29	Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 2167-2172.	2.0	15
30	Cabozantinib in advanced renal cell carcinoma: a METEOR impact on clinical practice. <i>Translational Andrology and Urology</i> , 2016, 5, 974-976.	0.6	2
31	Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience. <i>Therapeutic Advances in Urology</i> , 2016, 8, 319-326.	0.9	25
32	HER2 loss in HER2 ⁺ positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research. <i>International Journal of Cancer</i> , 2016, 139, 2859-2864.	2.3	94
33	Toward the molecular dissection of peritoneal pseudomyxoma. <i>Annals of Oncology</i> , 2016, 27, 2097-2103.	0.6	59
34	Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer. <i>Oncologist</i> , 2016, 21, 988-994.	1.9	94
35	Perioperative triplet chemotherapy plus bevacizumab (bev) in patients with borderline resectable colorectal cancer liver metastases (CLM): Preliminary safety and activity. <i>Annals of Oncology</i> , 2016, 27, vi161.	0.6	1
36	GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study. <i>Journal of Translational Medicine</i> , 2016, 14, 125.	1.8	36

#	ARTICLE	IF	CITATIONS
37	Urachal carcinoma: towards a precision medicine. <i>Translational Cancer Research</i> , 2016, 5, S1307-S1310.	0.4	5
38	Single-Agent Panitumumab in Frail Elderly Patients With Advanced <i>RAS</i> and <i>BRAF</i> Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope. <i>Oncologist</i> , 2015, 20, 1261-1265.	1.9	42